Latest news
Tasuku Kitada, co-founder, president, and head of R&D at Strand Therapeutics, is a long-time believer in mRNA technology. The company is developing 'programmable' mRNA drugs through synthetic biology, aiming to achieve single-dose, precise treatment in areas such as oncology. Kitada's upbringing has shaped his high tolerance for change and risk, which he regards as a key trait for entrepreneurs.
Colossal Biosciences is dedicated to resurrecting extinct species such as the woolly mammoth. Its spun-out startup, Form Bio, commercializes an internally developed bioinformatics platform designed to simplify CRISPR gene editing, data sharing, and experimental workflows, thereby accelerating drug development and biomanufacturing. The platform has secured $30 million in Series A funding and collaborates with institutions like Harvard University.
Nearly two decades after launching its annual PharmaVoice 100 list, PharmaVoice has announced a shift in editorial strategy to multiple year-round series (such as First 90 Days, Trailblazers, etc.) to continuously showcase industry leaders. Submissions are open on an ongoing basis, and nominations of suitable candidates are welcome.